- Home
- NXTC vs EVGN Comparison
NXTC vs EVGN Comparison
Compare NXTC & EVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- EVGN
- Stock Information
- Founded
- NXTC 2015
- EVGN 1999
- Country
- NXTC United States
- EVGN Israel
- Employees
- NXTC N/A
- EVGN N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- EVGN Agricultural Chemicals
- Sector
- NXTC Health Care
- EVGN Industrials
- Exchange
- NXTC Nasdaq
- EVGN Nasdaq
- Market Cap
- NXTC 13.0M
- EVGN 11.6M
- IPO Year
- NXTC 2019
- EVGN N/A
- Fundamental
- Price
- NXTC $5.76
- EVGN $1.22
- Analyst Decision
- NXTC Strong Buy
- EVGN Strong Buy
- Analyst Count
- NXTC 2
- EVGN 1
- Target Price
- NXTC $25.50
- EVGN $3.50
- AVG Volume (30 Days)
- NXTC 16.7K
- EVGN 46.1K
- Earning Date
- NXTC 11-06-2025
- EVGN 08-19-2025
- Dividend Yield
- NXTC N/A
- EVGN N/A
- EPS Growth
- NXTC N/A
- EVGN N/A
- EPS
- NXTC N/A
- EVGN N/A
- Revenue
- NXTC N/A
- EVGN $9,444,000.00
- Revenue This Year
- NXTC N/A
- EVGN N/A
- Revenue Next Year
- NXTC N/A
- EVGN $63.64
- P/E Ratio
- NXTC N/A
- EVGN N/A
- Revenue Growth
- NXTC N/A
- EVGN N/A
- 52 Week Low
- NXTC $2.69
- EVGN $0.95
- 52 Week High
- NXTC $19.20
- EVGN $3.32
- Technical
- Relative Strength Index (RSI)
- NXTC 66.21
- EVGN 45.51
- Support Level
- NXTC $5.19
- EVGN $1.16
- Resistance Level
- NXTC $5.15
- EVGN $1.29
- Average True Range (ATR)
- NXTC 0.27
- EVGN 0.06
- MACD
- NXTC 0.08
- EVGN -0.00
- Stochastic Oscillator
- NXTC 89.05
- EVGN 35.00
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About EVGN Evogene Ltd
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment, followed by Industry.